The Montana Cancer Consortium (MCC) NCORP Community Site will coordinate, support and improve the activities of physicians, cancer centers and hospitals across the entire state of Montana, as w/ell as portions of Northern Idaho and Wyoming, to maximize patient access to the highest levels of cancer care, especially accrual to NCI-sponsored clinical trials. In addition, MCC NCORP will design, participate in and influence cancer care delivery research, helping inform and speed validated care innovations into clinical practice. The region has been characterized as 'mega-rural'with severe access to care due to the vastness of the geography, lack of university-based treatment and research facilities, and lack of primary care providers. It is also home to seven American Indian Reservations, where issues of poverty, distance, and cultural taboos surrounding cancer care discussion and treatment create special disparities to prevention, early diagnosis, treatment and survivorship of cancer. MCC is an independent not-for-profit institution that exists to maximize access to clinical treatment trials and research through centralized services and support for member physicians and sites that might not otherwise offer access to these critical opportunities. The MCC NCORP Community Site consists of ten member components and six subcomponents that collectively will serve over one million residents in an area covering over 200,000 square miles. Membership includes 53 Board Certified oncologists, virtually every practitioner in the region and their respective hospitals and clinics, representing all cancer car specialty areas. MCC core staff managed the NCI Community Cancer Oncology Program (CCOP) since 1996 and includes a component site selected as an NCI National Community Cancer Centers Program (NCCCP) since 2007. MCC NCORP is affiliated with five national research bases, and is poised to provide and support expanded access to state-of-the-art cancer treatment, prevention, and control through NCI-sponsored clinical trials while improving the delivery of cancer care through research.

Public Health Relevance

The uniquely rural and medically underserved population of Montana, Northern Idaho and Northern Wyoming offers stimulating challenges for implementing NCI-sponsored clinical trials. The collective experience of the component sites in successful clinical trial enrollment and care delivery research on both rural and American Indian underserved populations will benefit NCORP's diversity and disparity goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189872-01
Application #
8790608
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Pearson, Deborah
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$630,000
Indirect Cost
Name
Montana Cancer Consortium
Department
Type
DUNS #
802713917
City
Billings
State
MT
Country
United States
Zip Code
59101
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32